Lumera Corporation Announces $2.2 Million Air Force Contract |
(Archive News Story - Products mentioned in this Archive News Story may or may not be available from the manufacturer.)
GigOptix Inc.
2400 Geng Road, Suite 100
Palo Alto, CA, 94303
USA
Press release date: March 20, 2008
BOTHELL, Wash.--March 20, 2008--Lumera Corporation (NASDAQ:LMRA), a leader in the field of photonic communications, announced today that it had received a contract from the US Air Force Research Laboratory valued at approximately $2.2 million to fabricate low driving voltage, reliable electro-optic modulators using Lumera's high-performance organic polymers.
"Current concepts of phased array radar and high-performance satellite systems require high-bandwidth electro-optic modulators with low driving voltages and wide bandwidths," said Dr. Raluca Dinu, Vice President, Electro-Optic Business Unit. "Lumera's EO devices have made significant strides in reaching these very aggressive goals, and we look forward to meeting the Air Force's requirements over the course of the contract."
RF photonics, in which optical components and optical fiber are used to process and distribute high-speed electrical signals, may provide the high bandwidth, reduced weight and size, and the immunity to electromagnetic interference that are crucial for future high-performance satellites and phased array radars. Due to the intrinsic dielectric properties of organic polymers and the great diversity of techniques used to design materials at the molecular level, electro-optic polymer devices are well suited to meeting these challenges.
About Lumera
Lumera is a leader in photonic communications. The company designs electro-optic components based on proprietary polymer compounds for the telecommunications and computing industries. Through its wholly owned subsidiary, Plexera Bioscience LLC, the company is also in the bioscience industry. Plexera is focused on providing the life sciences market with tools, content, and methods to simplify and accelerate proteomic discovery for therapeutic antibodies as well as predictive biomarkers. For more information, please visit lumera.com.
CONTACT:
The Summit Group Communications
Todd Wolfenbarger, 801-595-1155
Cell: 801-244-9600
SOURCE: Lumera Corporation
|
|
|
|
|
|
| 
